Bevacizumab,Durvalumab,Olaparib,Carboplatin,Paclitaxel
AstraZeneca,roche,Merck
['imfinzi', 'ovarian', 'brca', 'lynparza']
ovarian cancer patients without brca mutations benefit from lynparza, imfinzi plus standard of care. data presented at asco suggests that patients with brca-wildtype tumors could benefit from a regimen comprising the parp and checkpoint inhibitors... 